NeoGenomics, Inc. announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.
The partnership makes it possible for patients with specific biomarkers to get early support
FT. MYERS, FL / ACCESSWIRE / January 24, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a strategic partnership with the Biomarker Collaborative to help cancer patients who test positive for specific biomarkers connect to support groups that include patients with similar findings.
Now, when a lung cancer biomarker is identified through NeoGenomics’ testing, the results will include a resource page designed to educate patients on any identified biomarker, and it will connect them to support groups and peers instantly. The resource page is a discussion starting point helping empower patients to better understand their diagnosis with the support of peers walking a similar journey.
Mark Mallon, CEO of NeoGenomics, said, “We are honored to partner with the Biomarker Collaborative to expand our patient offering and fulfill our mission of saving lives by improving patient care. This is a historic day for NeoGenomics as we continue to optimize our patient program.”
The Biomarker Collaborative is a community of biomarker groups dedicated to helping patients with biomarkers live normal lives. The Biomarker Collaborative brings patients together to create a community, navigate the healthcare system, advocate, increase screening, ensure patients receive comprehensive biomarker testing, and support access to clinical trials.
Gina Hollenbeck, Co-President of the Biomarker Collaborative, said “This is a dream come true for the Biomarker Collaborative Member Groups, not only for patients who are newly-diagnosed but for patients who may not even have had a biomarker testing report ordered until well into treatment where they find out for the first time through NeoGenomics’ “Patient Resource” page in the report-the biomarker that is truly driving their cancer.” Added John Hallick, Co-President of the Biomarker Collaborative, “Both the patient and the patient’s oncologist will now see in the actual report ordered by the oncologist and issued by NeoGenomics that there is a biomarker group directly relevant to the patient’s diagnosis.”
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward Looking Statements
Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “plan,” “potential” and other words of similar meaning. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2021, as such information has been updated in subsequent SEC filings. As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. NeoGenomics routinely posts information that may be important to investors in the “Investor Relations” section of its website atwww.neogenomics.com. The Company encourages investors and potential investors to consult the NeoGenomics website regularly for important information about NeoGenomics.
For further information, please contact:
NeoGenomics, Inc.
Doug Brown
Chief Strategy and Corporate Development Officer
T: 239.768.0600 x2539
M: 704.236.2064
doug.brown@neogenomics.com
Charlie Eidson
Director, Investor Relations and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
charlie.eidson@neogenomics.com
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/685056/NeoGenomics-First-to-Partner-with-Biomarker-Collaborative-and-Deliver-Patient-Resources-Along-with-Oncology-Testing-Results
